BIOTRICITY INC - BTCY STOCK NEWS

Biotricity Inc. (NASDAQ:BTCY) announced its CEO, Waqaas Al Siddiq, will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 12:15 p.m. ET. The presentation will cover the company's strategic outlook for 2022, recent developments, and new products, including the Biokit bundle of wireless cardiac data devices. Biotricity aims to expand its market share and enhance shareholder value through its technology leadership and product pipeline. A replay of the presentation will be accessible on the corporate website for 30 days.

Biotricity Inc. (NASDAQ:BTCY) announces the upcoming launch of its Biokit, a connected personal medical device kit designed to enhance home-based health monitoring. The device aims to tackle challenges faced with existing products, aligning with the $18.4 billion North American portable medical device market. CEO Dr. Waqaas Al-Siddiq will present the company's long-term strategy at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021. This initiative positions Biotricity as a key player in remote monitoring and chronic care management.

Biotricity Inc. (NASDAQ:BTCY) announces the launch of its new Biokit, a personal medical device kit comprising an FDA-cleared digital thermometer, pulse oximeter, and blood pressure cuff. The kit aims to enhance remote cardiac monitoring and will be available in Q1 2022. These devices integrate with Biotricity's ecosystem, allowing real-time data sharing between patients and physicians. This launch is expected to expand the company's addressable market in the $18.4 billion North American portable medical device sector, aligning with Biotricity's goal to support cardiac patients effectively.

Biotricity, Inc. (NASDAQ:BTCY) announced a successful underwritten public offering, resulting in total gross proceeds of approximately $16 million. The offering, which closed on August 30, 2021, saw the underwriter partially exercise its option to purchase 382,331 additional shares, increasing the total shares sold to 5,382,331. This offering aligns with an effective shelf registration statement. H.C. Wainwright & Co. managed the offering, and it is aimed at advancing Biotricity's healthcare technology solutions.

Biotricity, Inc. (NASDAQ:BTCY) announced continued sales growth driven by the FDA-approved Bioflux mobile cardiac telemetry device, achieving a 290% year-over-year revenue increase in FY22-1Q and approximately 49% sequential growth. The company recently completed a $15 million equity raise and listed on the Nasdaq. CEO Waqaas Al-Siddiq will present at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand from September 13-15, 2021. The focus will be on sales expansion and product portfolio growth to enhance the total addressable market.

Biotricity, Inc. (NASDAQ:BTCY) has successfully closed an underwritten public offering, raising approximately $15 million by selling 5 million shares at $3.00 each. The underwriter has a 30-day option to buy an additional 750,000 shares. Proceeds from the offering will be allocated for general corporate purposes, including working capital and potential acquisitions. This offering was conducted under an effective registration statement declared by the SEC. Biotricity focuses on remote health monitoring solutions for chronic care management.

Biotricity Inc. (BTCY) announced a public offering of 5,000,000 shares of common stock, priced at $3.00 per share, totaling approximately $15 million in gross proceeds. The offering includes a 30-day option for the underwriter to purchase an additional 750,000 shares. The closing is expected on August 30, 2021, with shares listed on the Nasdaq Capital Market as of August 26, 2021. H.C. Wainwright & Co. is the sole book-running manager. The shares are offered through a prospectus filed with the SEC.

Biotricity (OTCQB:BTCY) has announced plans for an underwritten public offering of its common stock as it prepares for a potential listing on the Nasdaq Capital Market. The offering will include a 30-day option for the underwriter to purchase additional shares. Funds raised will support general corporate purposes like working capital and acquisitions. The offering is subject to market conditions and is made under an effective shelf registration statement filed with the SEC.

Biotricity (OTCQB:BTCY) has reported impressive results for Q1 of fiscal 2022, marking a record revenue of $1.76 million, representing a 290% year-over-year growth, the ninth consecutive quarter of triple-digit growth. This also reflects a 49% sequential increase compared to the previous quarter. Operating expenses grew modestly by 17% to $4.2 million, indicating the scalability of their business model. The company awaits FDA approval for its new Biotres holter product, poised for a swift launch. Future revenue growth is projected as the company continues to expand its market presence.